© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
835952 |
As an accredited (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
(R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole stands out among modern indole derivatives, carving a unique path in chemical research and production. The structure combines a brominated indole core with a methylpyrrolidine side chain, translating into a compound with a distinct profile. Naming this structure in everyday conversation gets clumsy, but the chemistry community knows why such attention flows to this molecule.
The world of indole chemistry opens up with compounds like this. Though the name takes a bit to wrap your tongue around, these features hint at applications ranging from advanced material synthesis all the way to roles in pharmacology. Not all indole-related chemicals capture so much attention. The addition of a bromine atom at the 5-position, alongside a methylated pyrrolidine, brings new opportunities in reactivity and selectivity.
Details on model numbers or catalog listings help chemists keep track, but in lived experience, structure means more than a label. The molecule’s backbone—an indole ring—takes a well-explored base and changes its game with the 5-bromo substitution. The choice of the R-enantiomer reflects an eye for chirality, knowing that the three-dimensional orientation of atoms does more than shift a label on paper. It actually dictates how the compound behaves, especially in biological contexts.
Specifically, the methyl-pyrrolidine attached at the 3-position takes this molecule down routes inaccessible to simple indoles or their non-brominated cousins. Every modification alters interaction with enzymes and catalysts. Someone working in the lab will find that little changes send shockwaves down the experimental path—yielding higher selectivity or pulling out different product mixtures compared to, say, a 5-unsubstituted or racemic analog. Even if the fine details of melting points and purity percentages matter during procurement, what tends to leave an impression is how this compound reacts to your hands-on techniques.
A lot of chemicals fit cleanly into bottles, never causing a fuss. This compound doesn’t fall into that tradition. Handling (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole reminds me of the first time I worked with a chiral intermediate during grad school—a moment that pushed me to recognize the subtleties in rotational configurations. Recrystallization works, but only if you respect the balance of solvents and don’t rush the process. Watching the crystals form under the right conditions gives more than aesthetic pleasure; it signals a level of purity essential for rigorous science.
The core structure carries some heft, but nothing overly tricky about standard measurements. Solid at room temperature, it sometimes holds static on spatulas; grounding glassware becomes second nature. Odor is mild, nothing alarming, but enough to remind anyone nearby of active aromatic compounds. Storage makes a difference for high-purity work. I always keep it in amber vials inside a desiccator, protecting fidelity. It doesn’t demand unusual handling, but treating it like a routine solid has never served me well when prepping for high-precision synthesis.
Beyond its structure, the real value of this compound emerges through its uses and behavior in experiments. I’ve seen labs pivot from other indole derivatives to this one for clear reasons: it often brings higher selectivity when aiming for specific targets. Risks of side reactions drop, and yields inch higher—details that mean real savings in time and material costs. In weekly group meetings, graduate students and postdocs speak up when a new analog boosts efficiency by even a few percent. There’s no glamour in raw numbers, but increased throughput catches attention in academic and industrial settings.
The presence of bromine at the 5-position fits more than a textbook model. That halogen offers a handle for further functionalization. Cross-coupling chemistry becomes more accessible—think Suzuki or Buchwald-Hartwig reactions. This increases versatility, enabling labs to attach a wide array of substituents, rapidly iterating on molecular libraries for lead identification. The indole body resists unwanted decomposition, and the specific R-stereochemistry establishes interactions with chiral environments, particularly in drug discovery projects. Time after time, this option outpaces earlier generation indoles for such iterative work.
The chemical industry values molecules that serve many roles. (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole slips easily into several workflows. Pharmaceutical researchers look to it as an intermediate for drug candidates, knowing that small tweaks might flip a compound from inactive to active. In my own work, starting with this scaffold opened up a broader set of kinase inhibitor explorations—models that previously needed more steps and actually more expense. Fewer synthetic steps due to pre-installed functionality become a big deal when scaling up.
For those venturing into material science, the unique reactivity of the bromo substitution helps build more complex molecules—such as functionalized polymers or dyes—directly from the indole base. Friends in the field talk about the ease of introducing further aromatic rings, leveraging the ready reactivity of the bromine. This aspect ensures people across both academia and industry keep the compound close in their toolkit.
In medicinal chemistry, molecule shape dictates how it fits and binds to target protein pockets. Here, the “R” chiral center and the methylpyrrolidine tail combine to make a distinctive fit—potentially beneficial for selectivity or metabolic stability. Real-world testing, of course, establishes whether promise matches outcome, but starting from a robust indole increases odds more than fumbling with less specific derivatives.
Chemists like a challenge, so they often run side-by-side comparisons of new chemicals. The biggest gains of (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole stem from its tailored substitutions. Unlike plain indole or non-chiral versions, it supports more selective transformations. Having that bromine at exactly the 5-position accelerates access to derivatives that plain 3-pyrrolidinyl indole cannot reach in a single step.
There’s no lack of commercially available indole derivatives. Laboratories used to lean heavily on 5-hydroxy or 5-methoxy analogs—these appear in early serotonin-mimicking research or as dyes. The bromine marks a clear difference, both in how readily cross-coupling partners attach and in how the electronic profile shifts interaction patterns. Those who have switched to this compound appreciate the efficiency, noting fewer byproducts and smoother purifications. These details might not sound dramatic, but spend a few late nights in a chemistry lab, and every edge matters.
The addition of the chiral methylpyrrolidine group, specifically in the R-configuration, distinguishes it from racemic mixtures. In fields where biological activity hinges on stereochemistry, such as drug development or natural product analogs, the difference between a chiral and non-chiral intermediate means everything. Biological targets may respond to one enantiomer while ignoring or even being harmed by another. Decisions at this level ripple out to safety, regulatory review, and final therapeutic effectiveness.
Even with clear strengths, this compound presents challenges that require experience and problem-solving. The combination of a bromo group and a chiral side chain increases synthetic complexity, which sometimes translates to higher price or supply bottlenecks. Sourcing the R-enantiomer requires attention to reputation—shoddy chiral resolution lingers on the shelf but wreaks havoc during synthesis. In my experience, chasing down odd byproducts traces back to impure starting material more often than flawed technique. This lesson gets learned the hard way if procurement skips standard checks.
The presence of a bromine atom, while a blessing for cross-coupling, can complicate downstream chemistry—sometimes reacting in unexpected ways when coupled with aggressive reductive or nucleophilic reagents. One memory stands out: a multi-step route veered off course when a planned reduction nipped off the bromine, trashing the whole sequence. Careful planning and pilot reactions tend to mitigate most surprises. Documentation of each run provides a guide rail for future work.
Handling this indole isn’t without occupational safety considerations, either. Its structure doesn’t scream high danger, yet inhalation or direct, prolonged contact carries risks—standard gloves, goggles, and ventilation remain non-negotiables, shaped as much by personal accident stories as by paperwork. Disposal protocols deserve attention, too. Brominated compounds require special attention to avoid long-term waste issues.
A robust body of peer-reviewed studies backs up experiences in the lab. Several articles report improved yields and selectivity in Suzuki-Miyaura couplings and related cross-coupling reactions when using bromo-substituted indoles. The literature also explores stereochemical influences on binding affinity for pharmacological targets. It’s not only anecdotal: comparison tables in those studies spell out performance gains, showing that racemic or positional isomers often lag in critical metrics.
Case studies from pharmaceutical research highlight the role of this derivative in assembling small molecule libraries for hit discovery. These accounts, shaped by daily struggles in drug hunting, point toward a trend—greater demand for chiral, functionally diverse intermediates. This compound, with its rich toolkit possibilities, fits the evolving needs of discovery teams.
Every time a newer analog enters the market, curious chemists run head-to-head screenings. Consistently, (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole tops the charts for reliability, clean reactions, and predictable performance in key transformations. Academic reviews suggest there’s no single magic bullet, but this one clearly lands in the upper echelon.
One talking point that surfaces in professional circles revolves around supply chain reliability. Trusted suppliers remain key—price fluctuations and purity swings plagued labs a decade ago, but reports suggest that high-quality batches now reach a wider network. The growth of specialized chemical vendors reflects demand. Procurement officers in industry keep close tabs, favoring sources known for tight batch-to-batch consistency.
Regulatory agencies keep one eye on potential environmental and safety hazards, especially for brominated aromatic compounds. My experience mirrors that of many colleagues: regular reviews of new research impact purchasing decisions. Transparent, well-documented sourcing increases trust, feeding a feedback loop that benefits everyone. Collaboration between laboratories, suppliers, and oversight bodies results in improvements in traceability and mitigation of potential hazards.
The impact of using higher specificity chemical precursors like this indole derivative isn’t limited to incremental yield bumps. Over the last few years, my lab saw reduced frequency of failed syntheses traced to unreliable starting material. Grant reports reflect this uptick in efficiency—fewer delays, smoother write-ups, and more time for exploration rather than troubleshooting supply issues.
Some teams in the medicinal chemistry sphere pivoted projects to focus entirely on derivatives accessible from this compound. They often cited ease of functional group interconversion and rapid analog expansion during hit-to-lead steps. These decisions funnel resources and talent into more productive avenues, with a visible impact on publication rates and patent filings.
Cross-talk with colleagues at conferences reinforces one key theme: select starting materials shape the trajectory of research more than flashy equipment or high-throughput robotics. Bench chemists know that progress emerges from bread-and-butter chemicals that support broad, reliable experimentation.
Challenges connected to price and purity require more than wishful thinking. A few practical moves help keep research on track. Sourcing from suppliers with clear batch analytics and a history of quality helps guarantee consistent performance. Lab-based quality checks—NMR, HPLC, mass spec—verify supplier claims and catch problems early.
For those troubled by supply costs, pooling orders with other labs or negotiating bulk rates brings down per-unit expense. Setting up shared inventories across institutional partners creates a buffer, especially during global supply hiccups.
Dealing with waste and safety demands accountability. Establishing clear protocols for handling and disposing of bromine-containing intermediates reduces downstream risks. In-house reminders about PPE, combined with routine safety walkthroughs, keep colleagues safe. Including training on new compounds as soon as they enter the lab smooths the integration process.
On the technical side, developing alternative synthetic routes, especially those reducing hazardous byproducts or simplifying isolation steps, could further unlock the promise of this molecule. Open sharing of optimized procedures—either in publications or professional networks—fast-tracks progress industry-wide.
Spending years at the bench or managing projects clarifies that outcomes hardly rest on luck. Reproducibility, clean data, and strong grant outcomes often trace back to starting materials like (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole. The smallest shift, a misplaced functional group or a deviation in chirality, throws off entire research programs. Practiced eyes and steady hands keep operations running, but only if supported by reliable intermediates.
Chemists, by nature, distrust hype and rely on results from their own hands or people they trust. Each new experiment with this compound, from cross-coupling to pharmacological screening, either validates its utility or prompts a hard look for something better. Over time, compounds like this earn their stripes not from advertising but from the accumulation of successful projects and the confidence of experts who put them to work.
The chemistry landscape shifts quickly. Over the next few years, continued demand for functionally rich, chiral indole derivatives seems certain. The rise of automated synthesis, AI-driven drug discovery, and collaborative global projects creates more opportunities for this molecule to play a role. Many anticipate that as routes improve and costs drop, expanded access will allow more small research teams and startups to leverage its properties.
Science, at its heart, thrives on concrete results and the relentless pursuit of improvement. Each generation of indole chemistry builds on the last, reflecting an evolution not only in synthetic methodologies but also in the collective knowledge and experience shared by those dedicated to advancing the field. (R)-5-Bromo-3-((1-Methylpyrrolidin-2-Yl)Methyl)-1H-Indole fits firmly into this tradition—testament to the ongoing dialogue between bench, desk, and real-world application.
